An open-label, single-center, phase 1/2 study of chemoradiotherapy and AT-101 in patients with locally advanced esophageal or gastroesophageal junction cancer (AT-101-CS-102).

Trial Profile

An open-label, single-center, phase 1/2 study of chemoradiotherapy and AT-101 in patients with locally advanced esophageal or gastroesophageal junction cancer (AT-101-CS-102).

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 18 Aug 2011

At a glance

  • Drugs AT 101; Docetaxel; Fluorouracil
  • Indications Gastric cancer; Oesophageal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Ascenta Therapeutics
  • Most Recent Events

    • 18 Aug 2011 Status changed from recruiting to active, no longer recruiting as reported by M.D. Anderson Cancer Center.
    • 01 Jan 2011 Status changed from active, no longer recruiting to recruiting as reported by M.D. Anderson Cancer Center record.
    • 30 Apr 2010 Status changed from recruiting to active, no longer recruiting as reported by M.D. Anderson Cancer Center record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top